Transplant immunology最新文献

{"title":"Risk factors for acute rejection in pediatric kidney transplantation.","authors":"Roman Gorchs, Matt Stout, Brooke Cohen, Jaden Ju, Eileen Brewer, Nhu Thao Nguyen Galvan, Abbas Rana","doi":"10.1016/j.trim.2025.102273","DOIUrl":"https://doi.org/10.1016/j.trim.2025.102273","url":null,"abstract":"<p><strong>Background: </strong>Acute rejection in pediatric kidney transplant patients can increase posttransplant costs and lead to limited survival of the graft. Identifying key risk factors for acute rejection in pediatric kidney recipients may allow for physicians to better tailor immunosuppressant regimens and decrease the occurrence of acute rejection.</p><p><strong>Methods: </strong>A retrospective analysis was performed using kidney transplantation data provided by the United Network for Organ Sharing (UNOS) for patients younger than 18 years old who received their first kidney transplant between January 2005 and December 2022. The resulting study population consisted of 10,126 patients over the 18-year span. Risk factors for acute rejection in the first year post-transplant were identified using a multivariate analysis.</p><p><strong>Results: </strong>Several variables were found to be statistically significant risk factors for acute rejection, including donor age ≤ 10 (Odds Ratio 1.44), Obese BMI (BMI-for-age z-score > 2.0), (Odds Ratio 1.22), a 6 Human Leukocyte Antigen (HLA) mismatch (Odds Ratio 1.22) and recipient age between 15 and 18 (Odds Ratio 1.21). Multiple factors were found to be protective, including male sex (Odds Ratio 0.85) and recipient age between 5 and 10 (Odds Ratio 0.79).</p><p><strong>Conclusions: </strong>The results indicate several significant risk factors such as the recipient age, Body Mass Index, sex and the number of HLA mismatches between the donor and the recipient. Physicians should consider these factors when personalizing immunosuppressive regimens for pediatric kidney transplant patients.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102273"},"PeriodicalIF":1.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical significance of CD45RA+FOXP3low naïve and CD45RA−FOXP3high effector/memory Treg subsets in the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","authors":"Mani Ramzi ,&nbsp;Mohammadnabi Sanaei ,&nbsp;Maryam Hesamadini ,&nbsp;Hossein Golmoghaddam ,&nbsp;Mehdi Kalani ,&nbsp;Nargess Arandi","doi":"10.1016/j.trim.2025.102272","DOIUrl":"10.1016/j.trim.2025.102272","url":null,"abstract":"<div><h3>Introduction</h3><div>It has been proposed that regulatory T cells (Tregs) might be involved in the induction of transplantation tolerance after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, little is known about the role of Treg subsets in allo-HSCT outcomes, including the development of acute graft-versus-host disease (aGVHD). Herein, we assessed for the first time the association between the frequency of regulatory T cell (Treg) subsets, including CD45RA⁺FOXP3^low naïve (nTregs) and CD45RA⁻FOXP3^high effector/memory Tregs (eTregs), and aGVHD occurrence during 90 days after allo-HSCT.</div></div><div><h3>Methods</h3><div>Twenty-four pairs of donors/recipients with hematologic malignancies who underwent HLA-matched allo-HSCT were enrolled. The frequencies of nTregs and eTregs were determined via four-color flow cytometry.</div></div><div><h3>Results</h3><div>Compared with non-aGVHD patients, aGVHD patients had a lower frequency of nTregs in their donors (*<em>P</em> = 0.016). The reconstitution rate of nTregs was significantly slower on day +60 post-allo-HSCT in aGVHD patients than in non-aGVHD patients (*<em>P</em> = 0.025).</div><div>Patients who received grafts with nTregs&lt;0.19 and a median frequency of nTregs&lt;0.13 and eTregs&lt;0.58 on day +30 after transplantation presented a relatively high cumulative incidence of aGVHD (*<em>P</em> = 0.039, *<em>P</em> = 0.032, and *<em>P</em> = 0.036, respectively). Multivariate analysis revealed that a low median total number of Tregs recovered on days +30 and + 60 post-allo-HSCT was associated with an increased incidence of aGVHD [HR = 0.199, 95 % CI, 0.041–0.969; *<em>P</em> = 0.046 and HR = 0.092, 95 % CI, 0.011–0.765; *<em>P</em> = 0.026, respectively].</div></div><div><h3>Conclusion</h3><div>This study provides novel insights showing that high donor nTreg content and rapid recovery of nTregs and eTregs early on day 30 post-transplantation are closely linked to protection from aGVHD.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102272"},"PeriodicalIF":1.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of high-dose versus standard-dose influenza vaccines in hematopoietic stem cell transplant recipients: A meta-analysis of randomized controlled trials","authors":"Ananda Pipphali Vidya ,&nbsp;Nicholas Jason Wijaya ,&nbsp;Dhabitah Zahraa Puteri Gathmir ,&nbsp;Naira Ayesha Kayla Kornel ,&nbsp;Muhammad Farhan ,&nbsp;Imelda Rosalyn Sianipar","doi":"10.1016/j.trim.2025.102270","DOIUrl":"10.1016/j.trim.2025.102270","url":null,"abstract":"<div><div>Given the vulnerability of hematopoietic cell transplant (HCT) patients to influenza infection and its complications, annual vaccination is recommended. However, vaccination was known to be less effective in these patients. Multiple studies have assessed various effects in HCT recipients after receiving different vaccine doses. However, the results have been inconclusive. This meta-analysis aims to provide a comprehensive analysis of the effectiveness and safety of HCT recipients when they receive a higher and standard dose of influenza vaccines. This study used PRISMA guidelines on several databases until Oct 25, 2024. We used ROB 2.0 and Review Manager 5.4 Software for further analysis. We included four low-risk of bias studies, and we conducted further analysis. The efficacy of HAI titer <span><math><mo>≥</mo></math></span> 1:40, &gt;4-fold, and confirmed influenza positives was comparable in both groups, with insignificant results in each follow-up group. However, the adverse effect was found significantly higher in the high-dose group, specifically the local adverse effect (<em>p</em> &lt; 0.0001). High-dose influenza vaccines showed higher adverse events and more confirmed influenza cases than standard-dose, suggesting standard-dose may be preferable post-HCT. These findings underscore the need for further research, particularly in diverse populations and vulnerable groups.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102270"},"PeriodicalIF":1.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful use of belumosudil in a patient with chronic ocular GVHD: A case report.","authors":"Xiaoli Lv, Huibo Li, Zhijian Li, Di Jin, Fei Leng, Jie Liu, Dan Guo, Shengjin Fan, Sheng Su","doi":"10.1016/j.trim.2025.102271","DOIUrl":"https://doi.org/10.1016/j.trim.2025.102271","url":null,"abstract":"<p><strong>Background: </strong>Belumosudil is a selective ROCK2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients who have failed at least two prior systemic therapies. By inhibiting ROCK2, Belumosudil can down-regulate the secretion of IL-21 and IL-17, and up-regulate regulatory T cells (Tregs), which serve to attenuate the inflammatory response. In addition, it can act as an antifibrotic by inhibiting the Rho-ROCK-MRTF pathway, as well as down-regulating the expression of pro-fibrotic genes and TGF-β signaling. Selective inhibition of ROCK2 also reduces M2-like macrophages and choroidal neovascularization, which further exerts antifibrotic effects. Therefore, belumosudil shows great potential in the treatment of chronic Graft-Versus-Host-Disease (cGVHD).</p><p><strong>Case presentation: </strong>We report the clinical course of a 39-year-old man with severe progressive chronic ocular GVHD (oGVHD), who showed significant improvement in ocular surface damage, including damage to the cornea and meibomian glands, as well as dry eye symptoms, after oral administration of belumosudil. Corneal leukoplakia and neovascularization were significantly reduced after treatment. Moreover, the patient's ocular surface symptoms remained stable without deterioration after cataract surgery. The patient's quality of life was significantly enhanced.</p><p><strong>Conclusion: </strong>We report the clinical outcomes of a patient with chronic oGVHD treated with belumosudil. The patient's clinical symptoms significantly improved, especially inflammation of the meibomian gland, corneal leukoplakia, and neovascularization. This highlights its application value in patients with cGVHD and provides a promising treatment option for patients with oGVHD.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102271"},"PeriodicalIF":1.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-transplant sensitization and its effect on heart transplant rejection and survival outcomes.","authors":"Kyung-Hwa Shin, Soo Yong Lee, Min Ho Ju, Hyun-Ji Lee","doi":"10.1016/j.trim.2025.102264","DOIUrl":"https://doi.org/10.1016/j.trim.2025.102264","url":null,"abstract":"<p><strong>Background: </strong>Sensitization of heart transplant (HT) recipients increases the risk of rejection. Assessment of sensitization using a calculated panel reactive antibody (cPRA) is crucial for evaluating transplant compatibility and predicting outcomes. This study investigated the impact of cPRA and pre-existing and de novo Human Leukocyte Antigen (HLA)-donor-specific antibodies (DSAs) on HT outcomes and aimed to identify recipients at a high risk of rejection.</p><p><strong>Methods: </strong>This retrospective study included 121 adult recipients of HT from a single institution (2014-2023). cPRA values, flow cytometric crossmatches (FCXM), and DSAs were analyzed for their associations with antibody-mediated rejection (AMR) and T cell-mediated rejection (TCMR).</p><p><strong>Results: </strong>Among the 121 HT recipients, 51.2 % experienced TCMR and 7.4 % experienced AMR. cPRA (I) ≥ 50 % was significantly associated with AMR, pre-existing DSA (pDSA), and positive FCXM. pDSA was present in 16.5 % of HT recipients and correlated with AMR but not mortality. De novo DSAs frequently emerged in 38 % of the recipients following TCMR episodes. Higher cPRA (I) levels correlated with increased rejection risk and shorter AMR-free survival.</p><p><strong>Conclusions: </strong>High cPRA (≥50 %) significantly predicted the risk of AMR and correlated with pDSA and positive FCXM results. Pre-transplant cPRA assessment is crucial for identifying high-risk recipients and optimizing management strategies to improve HT outcomes.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102264"},"PeriodicalIF":1.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of maintenance immunosuppressive therapy on FoxP3 and CD28 gene expression in low risk kidney transplant recipients.","authors":"May A Hassaballa, Mariam Onsy F Hanna, Ahmed Mohamed Radwan, Noussa M ElAdawi, Amal Kamal Helmy, Tarek Fayad, Mervat ElAnsary, Gamal Saadi","doi":"10.1016/j.trim.2025.102268","DOIUrl":"https://doi.org/10.1016/j.trim.2025.102268","url":null,"abstract":"<p><strong>Background: </strong>FoxP3 is a transcription factor expressed by regulatory T cells and is essential for their development and suppressive function. CD28 is a costimulatory receptor on T cells that binds to CD80 and CD86 on antigen-presenting cells, providing a signal required for T cell activation and survival. This study compared FoxP3 and CD28 gene expression in long-term kidney transplant recipients (KTR) maintained on immunosuppressive therapy with mammalian target of rapamycin inhibitors (mTORI) versus calcineurin inhibitors (CNI).</p><p><strong>Methods: </strong>The expression of FoxP3 and CD28 was assessed in immunologically low-risk KTR with stable graft function. KTR receiving CNI (n = 24) were compared with those who underwent early conversion to mTORI post-transplant (n = 20). All patients received a transplant from living donors and the median time since transplant was 60 months. Gene expression analysis was performed in the peripheral blood mononuclear cells by quantitative PCR.</p><p><strong>Results: </strong>FoxP3 expression differed significantly between treatment groups, with higher levels observed in the mTORI group compared to the CNI group (P = 0.025), while CD28 expression was comparable between groups. Among KTR receiving CNI therapy, FoxP3 expression was significantly lower in female recipients compared to males (P = 0.008); this difference was not observed in the mTORI group. In a multivariate analysis including age, sex, FoxP3 expression and immunosuppressive therapy, only mTORI therapy was significantly associated with higher estimated glomerular filtration rate [β = 22.66 (95 % CI = 3.41-41.91), P = 0.022].</p><p><strong>Conclusions: </strong>In stable KTR, long-term immunosuppression with mTORI is associated with higher FoxP3 expression and lower CD28 to FoxP3 expression ratio compared to CNI. Although FoxP3 expression differed between treatment groups, only mTORI therapy was independently associated with improved kidney function.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102268"},"PeriodicalIF":1.6,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of ABO-incompatible kidney transplantation in Argentina: A 10-years single-center experience","authors":"Carlos Chiurchiu ,&nbsp;Pehuén Fernández ,&nbsp;Walter Douthat ,&nbsp;Javier de Arteaga ,&nbsp;Esteban Metrebian ,&nbsp;Raul Colla ,&nbsp;Alejandro Martinez Colombres ,&nbsp;Guillermo Paladini ,&nbsp;Juan Carlos Damonte ,&nbsp;Virginia Damonte ,&nbsp;Luciana Mas ,&nbsp;Emanuel José Saad ,&nbsp;Jorge de la Fuente","doi":"10.1016/j.trim.2025.102266","DOIUrl":"10.1016/j.trim.2025.102266","url":null,"abstract":"<div><h3>Introduction</h3><div>ABO-incompatible (ABOi) kidney transplantation is a feasible option for patients without ABO-compatible (ABOc) living donors. However, its impact on rejection rates and long-term outcomes remains debated. This study aims to compare rejection incidence, graft survival, and patient outcomes between ABOi and ABOc kidney transplant recipients.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, observational, analytical cohort study at the Hospital Privado Universitario de Córdoba, including all ABOi living donor kidney transplants performed between July 2014 and August 2024. For each ABOi recipient, an ABOc counterpart was matched based on age (±5 years), transplant date (±1 year), and sex (when possible). Patients were followed for up to 10 years post-transplant. Immunosuppressive protocols and infectious prophylaxis followed institutional guidelines.</div></div><div><h3>Results</h3><div>Of 217 living donor kidney transplants, 33 (15.2 %) were ABOi. No significant differences were found between ABOi and ABOc groups in demographic or clinical baseline characteristics, except for donor age (<em>p</em> = 0.026). There were no differences in graft function, major complications, graft loss, or mortality between groups. Acute rejection occurred in 11 ABOi patients (9 humoral, 2 cellular) and 10 ABOc patients (5 humoral, 4 cellular, 1 mixed), with no significant differences. The 10-year overall patient survival was 82.8 % for ABOi and 83.7 % for ABOc, while death-censored graft survival was 96.4 % and 91.7 %, respectively. The non-use of thymoglobulin was the only independent predictor of rejection (aOR = 5.44; 95 % CI = 1.16–25.5; <em>p</em> = 0.031).</div></div><div><h3>Conclusion</h3><div>ABOi kidney transplantation demonstrates comparable long-term outcomes to ABOc transplantation. It is a viable and safe alternative for patients lacking ABO-compatible living donors.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102266"},"PeriodicalIF":1.6,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syngeneic hematopoietic stem cell transplantation from an identical twin sister in an AML patient: “A case report highlighting accelerated engraftment and reduced transfusion requirements”","authors":"Ehsan Yazdandoust ,&nbsp;Abbas Hajifathali ,&nbsp;Zeinab Kaboli ,&nbsp;Sedigheh Amini-Kafiabad","doi":"10.1016/j.trim.2025.102267","DOIUrl":"10.1016/j.trim.2025.102267","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hematopoietic stem cell transplantation (HSCT) is among the most effective immunotherapeutic strategies for treating hematologic malignancies in both pediatric and adult patients. Its global use has been steadily increasing. Patients undergoing HSCT commonly require transfusion support with blood products until engraftment is achieved, and transfusion requirements can significantly affect post-transplant outcomes. Despite advancements that have improved survival rates, transplant-related mortality (TRM) continues to be a major obstacle to optimal outcomes.</div></div><div><h3>Case presentation</h3><div>We present the case of a 46-year-old woman diagnosed with acute myeloid leukemia (AML) harboring an FLT3-ITD mutation, who underwent allogeneic HSCT. The donor was her identical twin sister, with full HLA compatibility (a 10/10 match) and an identical ABO blood group (O positive). Notably, the patient exhibited rapid neutrophil and platelet engraftment by day +9, which is earlier than typically observed in transplants from fully matched related or unrelated donors. Furthermore, the patient did not require any red blood cell or platelet transfusions during the transplantation period and developed no signs of acute or chronic graft-versus-host disease (GVHD). She has remained disease-free with no evidence of relapse for over three years post-transplant.</div></div><div><h3>Conclusion</h3><div>HSCT from an identical twin donor may provide favorable clinical outcomes, including accelerated engraftment and reduced transfusion needs during the transplantation process.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102267"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing controls demonstrates a high prevalence of non-HLA antibody positivity using pre-defined cutoff threshold in a bead-based assay using healthy control population","authors":"A. Agrawal ,&nbsp;M. Zuccarelli ,&nbsp;L.L. Wakefield ,&nbsp;C.A. Schinstock ,&nbsp;M.J. Gandhi ,&nbsp;A.J. Bentall","doi":"10.1016/j.trim.2025.102265","DOIUrl":"10.1016/j.trim.2025.102265","url":null,"abstract":"<div><h3>Background</h3><div>Measuring non-HLA antibodies is a potentially important tool in assessing allograft dysfunction and needs to be correlated with clinical outcomes. Thus, determining the antibody distribution in healthy populations is important before correlating with clinical events. Using male blood donors, we selected a low immunological risk control cohort.</div></div><div><h3>Methods</h3><div>We analyzed samples from 92 male, non-transfused blood donors (donors) to assess the detection of antibodies in a normal population cohort using a non-HLA 33 antigen multiplex commercial assay.</div></div><div><h3>Results</h3><div>At manufacturer's suggested cutoff threshold (COT) of 75 % percentile, no donors had negative results and at 95 % percentile only three donors were negative across all 33 antigens. At each of the manufacturer's COT, the median (IQR) number positive antibody bead tests per donor was 13 (10–17), 11 (8–13) and 7 (5–10) at 75th, 85th and 95th percentile COT, respectively. There was poor correlation between manufacturer's COT and locally generated COT (range <em>r</em> = 0.520 to 0.595). The percentage of donors who had three or more positive antibody bead tests was: 98.9 % at 75th COT; 95.7 % at 85th COT and 93.5 % at 95th COT.</div></div><div><h3>Conclusions</h3><div>Considering the high proportion of positive results in a low immunological risk cohort, application of non-HLA antibody measurement in a diseased cohort is not optimal, and difficult to correlate with clinical events. Further studies to determine normal detection rates are needed for assay COT and clinical application in diseases.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102265"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of monocytic myeloid-derived suppressor cell recovery and interleukin-10 production on graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation","authors":"Arsa Thammahong ,&nbsp;Kitsada Wudhikarn ,&nbsp;Ponlapat Rojnuckarin ,&nbsp;Patsita Kansuwan ,&nbsp;Udomsak Bunworasate ,&nbsp;Chantiya Chanswangphuwana","doi":"10.1016/j.trim.2025.102263","DOIUrl":"10.1016/j.trim.2025.102263","url":null,"abstract":"<div><h3>Background</h3><div>Myeloid-derived suppressor cells (MDSCs) suppress immune responses. We hypothesized that MDSCs and their related cytokines/chemokines after receiving allogeneic hematopoietic cell transplantation (allo-HCT) impact graft-versus-host disease (GVHD) and infectious complications.</div></div><div><h3>Methods</h3><div>This study investigated the dynamics of MDSCs recovery using flow cytometry. Cytokines/chemokines were measured by the Luminex assay and correlated with clinical outcomes.</div></div><div><h3>Results</h3><div>Forty-nine patients who underwent allo-HCT at King Chulalongkorn Memorial Hospital from 2022 to 2023 were enrolled. The median age was 42 years. Most cases (81.6 %) were acute leukemia. Peripheral blood stem cells were collected from human leukocyte antigen-matched related/unrelated donors (85.7 %) or haploidentical donors (14.3 %). Forty-six patients (93.9 %) received myeloablative conditioning regimens. GVHD prophylaxis regimens were calcineurin inhibitor plus methotrexate (67.3 %) and post-transplantation cyclophosphamide (32.7 %). Acute GVHD occurred in 9 (18.4 %) patients with a median onset of 35 days. The percentage of monocytic MDSC (M-MDSC), interleukin-10 (IL-10) and CXCL2 levels on day+28 of acute GVHD patients were all significantly lower than non-GVHD patients (0.26 % vs. 0.55 %, <em>p</em> = 0.048, 15.45 pg/ml vs. 23.53 pg/ml, <em>p</em> = 0.041, and 201.44 pg/ml vs. 428.42 pg/ml, <em>p</em> = 0.029, respectively). Cytomegalovirus (CMV) reactivation was detected in 69.4 % of patients with a median onset of 39 days. CMV reactivation was related to higher M-MDSC percentage on day+14 and IL-10 on day+28 compared with no reactivation (0.76 % vs. 0.22 %, <em>p</em> = 0.047 and 24.35 pg/ml vs. 16.42 pg/ml, <em>p</em> = 0.003, respectively).</div></div><div><h3>Conclusion</h3><div>Delayed M-MDSC reconstitution and low IL-10 were associated with acute GVHD, while high numbers of M-MDSCs and higher IL-10 levels increased the risk of CMV reactivation.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102263"},"PeriodicalIF":1.6,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}